Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study - PubMed
6 hours ago
- #ALK-positive NSCLC
- #phase IV study
- #Lorlatinib
- Lorlatinib showed clinical benefit in ALK-positive metastatic NSCLC patients previously treated with second-generation ALK inhibitors.
- The objective response rate (ORR) was 42% with a median progression-free survival of 12.2 months.
- Intracranial ORR was 47% in patients with central nervous system metastases.
- Treatment-emergent adverse events were common (97% any-grade, 39% grade ≥3), but no treatment discontinuations due to related adverse events occurred.
- Results align with earlier phase I/II studies, confirming lorlatinib's efficacy and safety in this setting.